Drug Safety

, Volume 24, Issue 13, pp 947–959 | Cite as

Therapeutic Drug Monitoring Databases for Postmarketing Surveillance of Drug-Drug Interactions

  • Marianne Gex-Fabry
  • Luc P. Balant
  • Androniki E. Balant-Gorgia
Leading Article

Abstract

Drug-drug interactions can be associated with patient morbidity due to either increased toxicity or a potentially ineffective concentration. Because interactions cannot always be anticipated during drug development and actual patients receiving a drug for therapeutic use often differ from those included in clinical trials, postmarketing surveillance is essential. Therapeutic drug monitoring (TDM) databases offer a unique opportunity in this respect.

Prerequisites for TDM databases to provide valid information in a pharmacoepidemiological perspective include the following: precise description of exposure to the potentially interacting drugs; measurement of parent compound and active metabolites through accurate and precise analytical techniques; documentation of relevant patient characteristics that may act as confounding factors (e.g. gender, age, smoking habits); repeated assessments over time if possible; and sound pharmacokinetic framework for data selection, analysis and interpretation.

The contribution of TDM to the documentation of drug-drug interactions takes advantage of different possible study designs, discussed on the basis of recently published studies. The single case report plays an important role as an alert signal. It is illustrated for a patient on long-term treatment, who displayed an unexpectedly high clozapine concentration after the introduction of ciprofloxacin comedication. The prospective on and off comedication panel study shows advantages in terms of carefully selected inclusion criteria and control of treatment modalities. A study of the thioridazine-fluvoxamine interaction is presented, with patients followed on thioridazine monotherapy, after introduction of fluvoxamine and after its discontinuation. The main advantage of the retrospective large-scale TDM database screen is representativeness of patients actually treated, whereas drawbacks are related to quality of data and suitability for valid interpretation. Such an approach is illustrated by a review of data collected over 10 years of routine TDM that allowed documenting induction of nortriptyline metabolismby carbamazepine and inhibition by several phenothiazines. Finally, population pharmacokinetics is well suited to observational data collected for TDM purpose, provided quality is ascertained. Focus is placed on interindividual variability and relationship between pharmacokinetic parameters and patient characteristics, including comedication. The population approach is discussed with respect to a study that documented a 32% increase of haloperidol clearance associated with anticonvulsant comedication, in addition to effects of age and bodyweight.

Among factors to consider for improved effectiveness in the use of TDM databases for postmarketing surveillance of drug-drug interactions, integration of efficacy and safety data in future studies and communication of expert recommendations to prescribing physicians are essential.

Notes

Acknowledgements

This work has been prepared in the course of the authors’ employment at the Geneva University Hospitals, Geneva, Switzerland. No external funding nor conflict of interest was relevant to the content of this article.

References

  1. 1.
    Bjerrum L, Rosholm J, Hallas J, et al. Methods for estimating the occurrence of polypharmacy by means of a prescription database. Eur J Clin Pharmacol 1997; 53: 7–11PubMedCrossRefGoogle Scholar
  2. 2.
    Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. Drugs Aging 1998; 12: 485–94PubMedCrossRefGoogle Scholar
  3. 3.
    Grönroos P, Irjala K, Huupponen R, et al. A medication database — a tool for detecting drug interactions in hospital. Eur J Clin Pharmacol 1997; 53: 13–7PubMedCrossRefGoogle Scholar
  4. 4.
    European Agency for the Evaluation of Medicinal Products. Note for guidance on the investigation of drug interactions [online]. Available from URL: http://www.emea.eu.int/index/indexh1.htm [Accessed 2001 Sep 20]
  5. 5.
    US Food and Drug Administration. Guidance for industry. In vivo drug metabolism/drug interaction studies — study design, data analysis, and recommendations for dosing and labeling [online]. Available from URL: http://www.fda.gov/cder/guidance/index.htm [Accessed 2001 Sep 20]
  6. 6.
    Müller HJ, Gundert-Remy U. The regulatory view on drug-drug interactions. Int J Clin Pharmacol Ther 1994; 32: 269–73PubMedGoogle Scholar
  7. 7.
    Gross AS. Best practice in therapeutic drug monitoring. Br J Clin Pharmacol 1998; 46: 95–9PubMedCrossRefGoogle Scholar
  8. 8.
    Warner A. Setting standards of practice in therapeutic drug monitoring and clinical toxicology: a North American view. Ther Drug Monit 2000; 22: 93–7PubMedCrossRefGoogle Scholar
  9. 9.
    Keyler DE, VanDe Voort JT, Howard JE, et al. Monitoring blood levels of selected drugs. Remember to factor in the many confounding variables. Postgrad Med 1998; 103: 209–4PubMedCrossRefGoogle Scholar
  10. 10.
    Back DJ, Khoo SH, Gibbons SE, et al. Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection. Ther Drug Monit 2000; 22: 122–6PubMedCrossRefGoogle Scholar
  11. 11.
    McLeod HL. Therapeutic drug monitoring opportunities in cancer therapy. Pharmacol Ther 1997; 74: 39–54PubMedCrossRefGoogle Scholar
  12. 12.
    Yew WW. Therapeutic drug monitoring in antituberculosis chemotherapy. Ther Drug Monit 1998; 20: 469–72PubMedCrossRefGoogle Scholar
  13. 13.
    Johannessen SI. Plasma drug concentration monitoring of anticonvulsants. Practical guidelines. CNS Drugs 1997; 7: 349–65CrossRefGoogle Scholar
  14. 14.
    Mitchell PB. Therapeutic drug monitoring of psychotropic medications.Br J Clin Pharmacol 2000; 49: 303–12PubMedCrossRefGoogle Scholar
  15. 15.
    Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet 2000; 38: 191–204PubMedCrossRefGoogle Scholar
  16. 16.
    Brøsen K. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther Drug Monit 1996; 18: 393–6PubMedCrossRefGoogle Scholar
  17. 17.
    Glue P, Banfield C. Psychiatry, psychopharmacology and P-450s. Hum Psychopharmacol 1996; 11: 97–114CrossRefGoogle Scholar
  18. 18.
    Balant-Gorgia AE, Gex-Fabry M, Balant LP. Therapeutic drug monitoring and drug-drug interactions: a pharmacoepidemiological perspective. Thérapie 1996; 51: 399–402PubMedGoogle Scholar
  19. 19.
    Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions: evaluation of a paired approach for psychotropic medication. Ther Drug Monit 1997; 19: 1–10PubMedCrossRefGoogle Scholar
  20. 20.
    Gex-Fabry M, Balant-Gorgia AE, Balant LP. Potential of concentration monitoring data for a short half-life drug: analysis of pharmacokinetic variability for moclobemide. Ther Drug Monit 1995; 17: 39–46PubMedCrossRefGoogle Scholar
  21. 21.
    Whiting B, Kelman AW, Grevel J. Population pharmacokinetics. Theory and clinical application. Clin Pharmacokinet 1986; 11: 387–401PubMedCrossRefGoogle Scholar
  22. 22.
    Sheiner LB, Ludden TM. Population pharmacokinetics/dynamics. Annu Rev Pharmacol Toxicol 1992; 32: 185–209PubMedCrossRefGoogle Scholar
  23. 23.
    Gex-Fabry M, Balant-Gorgia AE, Balant LP, et al. Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data. Clin Pharmacokinet 1990; 19: 241–55PubMedCrossRefGoogle Scholar
  24. 24.
    Balant-Gorgia AE, Gex-Fabry M, Genet C, et al. Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors. Ther Drug Monit 1999; 21: 105–5PubMedCrossRefGoogle Scholar
  25. 25.
    Bates DW. Improving the use of therapeutic drug monitoring. Ther Drug Monit 1998; 20: 550–5PubMedCrossRefGoogle Scholar
  26. 26.
    Shapiro S. The role of automated record linkage in the postmarketing surveillance of drug safety: a critique. Clin Pharmacol Ther 1989; 46: 371–86PubMedCrossRefGoogle Scholar
  27. 27.
    Strom BL, Carson JL. Automated data bases used for pharmacoepidemiology research. Clin Pharmacol Ther 1989; 46: 390–4PubMedCrossRefGoogle Scholar
  28. 28.
    Hollister LE, Jones JK, Fisher S. Post-marketing surveillance of drugs. In: Prien RF, Robinson DS, editors. Clinical evaluation of psychotropic drugs: principles and guidelines. New York: Raven Press, 1994: 217–35Google Scholar
  29. 29.
    Ereshefsky L, Tran-Johnson T, Davis CM, et al. Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: evaluation of doxepin and imipramine — new data and review. Clin Chem 1988; 34: 863–80PubMedGoogle Scholar
  30. 30.
    Dahl ML, Sjöqvist F. Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics. Ther Drug Monit 2000; 22: 114–7PubMedCrossRefGoogle Scholar
  31. 31.
    Steinijans VW, Hartmann M, Huber R, et al. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 1991; 29: 323–8PubMedGoogle Scholar
  32. 32.
    Buur-Rasmussen B, Brøsen K. Cytochrome P450 and therapeutic drug monitoring with respect to clozapine. Eur Neuropsychopharmacol 1999; 9: 453–9PubMedCrossRefGoogle Scholar
  33. 33.
    McLellan RA, Drobitch RK, Monshouwer M, et al. Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. Drug Metab Dispos 1996; 24: 1134–8PubMedGoogle Scholar
  34. 34.
    Raaska K, Neuvonen PJ. Ciprofloxacin increases serumclozapine and N-desmethylclozapine: a study in patients with schizophrenia. Eur J Clin Pharmacol 2000; 56: 585–9PubMedCrossRefGoogle Scholar
  35. 35.
    Perry PJ. Therapeutic drug monitoring of atypical antipsychotics. Is it of potential clinical value? CNS Drugs 2000; 13: 167–71CrossRefGoogle Scholar
  36. 36.
    Centorrino F, Baldessarini RJ, Kando JC, et al. Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients. J Clin Psychopharmacol 1994; 14: 119–25PubMedCrossRefGoogle Scholar
  37. 37.
    Vaughan DA. Interaction of fluoxetine with tricyclic antidepressants. Am J Psychiatry 1988; 145: 1478PubMedGoogle Scholar
  38. 38.
    Bertschy G, Vandel S, Vandel B, et al. Fluvoxamine-tricyclic antidepressant interaction. Eur J Clin Pharmacol 1991; 40: 119–20PubMedCrossRefGoogle Scholar
  39. 39.
    Seifritz E, Holsboer-Trachsler E, Hemmeter U, et al. Increased trimipramine plasma levels during fluvoxamine comedication. Eur Neuropsychopharmacol 1994; 4: 15–20PubMedCrossRefGoogle Scholar
  40. 40.
    Balant-Gorgia AE, Ries C, Balant LP. Metabolic interaction between fluoxetine and clomipramine: a case report. Pharmacopsychiatry 1996; 29: 38–41PubMedCrossRefGoogle Scholar
  41. 41.
    Balant-Gorgia AE, Balant LP. Metabolic interaction between fluoxetine and tricyclic antidepressants: benefit for the patient or potential problem? J Subst Misuse 1997; 2: 5–7CrossRefGoogle Scholar
  42. 42.
    Haffen E, Vandel P, Broly F, et al. Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype. Pharmacopsychiatry 1999; 32: 232–4PubMedCrossRefGoogle Scholar
  43. 43.
    Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Drug interactions with newer antidepressants: role of human cytochromes P450. J Clin Psychiatry 1998; 59: 19–27PubMedGoogle Scholar
  44. 44.
    Carrillo JA, Ramos SI, Herraiz AG, et al. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. J Clin Psychopharmacol 1999; 19: 494–9PubMedCrossRefGoogle Scholar
  45. 45.
    Spina E, Avenoso A, Pollicino AM, et al. Carbamazepine coadministration with fluoxetine or fluvoxamine. Ther Drug Monit 1993; 15: 247–50PubMedCrossRefGoogle Scholar
  46. 46.
    Vandel S, Bertschy G, Baumann P, et al. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 1995; 31: 347–53PubMedCrossRefGoogle Scholar
  47. 47.
    Eap CB, Bertschy G, Powell K, et al. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. J Clin Psychopharmacol 1997; 17: 113–7PubMedCrossRefGoogle Scholar
  48. 48.
    Loonen AJM, Doorschot CH, Oostelbos MCJM, et al. Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study. Eur Neuropsychopharmacol 1999; 10: 51–7PubMedCrossRefGoogle Scholar
  49. 49.
    Daniel DG, Randolph C, Jaskiw G, et al. Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol 1994; 14: 340–3PubMedCrossRefGoogle Scholar
  50. 50.
    Jerling M, Bertilsson L, Sjöqvist F. The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline. Ther Drug Monit 1994; 16: 1–12PubMedCrossRefGoogle Scholar
  51. 51.
    Jerling M, Lindström L, Bondesson U, et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994; 16: 368–74PubMedCrossRefGoogle Scholar
  52. 52.
    Islam SI, Masuda QN, Bolaji OO, et al. Possible interaction between cyclosporine and glibenclamide in posttransplant diabetic patients. Ther Drug Monit 1996; 18: 624–6PubMedCrossRefGoogle Scholar
  53. 53.
    Spina E, Avenoso A, Facciola G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther Drug Monit 2000; 22: 481–5PubMedCrossRefGoogle Scholar
  54. 54.
    Leinonen E, Lepola U, Koponen H, et al. The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method. Ther Drug Monit 1996; 18: 111–7PubMedCrossRefGoogle Scholar
  55. 55.
    Hirokane G, Someya T, Takahashi S, et al. Interindividual variation of plasma haloperidol concentrations and the impact of concomitant medications: the analysis of therapeutic drug monitoring data. Ther Drug Monit 1999; 21: 82–6PubMedCrossRefGoogle Scholar
  56. 56.
    Jerling M. Population pharmacokinetics and pharmacodynamics: potential use for gathering dose-concentration-response.Eur J Drug Metab Pharmacokinet 1996; 21: 113–21PubMedCrossRefGoogle Scholar
  57. 57.
    Ereshefsky L, Saklad SR, Watanabe MD, et al. Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. J Clin Psychopharmacol 1991; 11: 296–301PubMedCrossRefGoogle Scholar
  58. 58.
    Morris RG, Black AB, Harris AL, et al. Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. Br J Clin Pharmacol 1998;46: 547–51PubMedCrossRefGoogle Scholar
  59. 59.
    Olesen OV. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Ther Drug Monit 1999; 21: 87–90PubMedCrossRefGoogle Scholar
  60. 60.
    Böttiger Y, Svensson JO, Ståhle L. Lamotrigine drug interactions in a TDM material. Ther Drug Monit 1999; 21: 171–4PubMedCrossRefGoogle Scholar
  61. 61.
    Hübner GI, Eismann R, Sziegoleit W. Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit 1999; 21: 536–9PubMedCrossRefGoogle Scholar
  62. 62.
    Lundmark J, Reis M, Bengtsson F. Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting. Ther Drug Monit 2000; 22: 446–54PubMedCrossRefGoogle Scholar
  63. 63.
    Liu H, Delgado MR. Improved therapeutic monitoring of drug interactions in epileptic children using carbamazepine polytherapy. Ther Drug Monit 1994; 16: 132–8PubMedCrossRefGoogle Scholar
  64. 64.
    De Vane CL, Grasela TH, Antal EJ, et al. Evaluation of population pharmacokinetics in therapeutic trials. IV. Application to postmarketing surveillance. Clin Pharmacol Ther 1993; 53: 521–8CrossRefGoogle Scholar
  65. 65.
    Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977; 5: 445–79PubMedGoogle Scholar
  66. 66.
    Aarons L. Software for population pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1999; 36: 255–64PubMedCrossRefGoogle Scholar
  67. 67.
    Williams PJ, Lane J, Murray W, et al. Pharmacokinetics of the digoxin-quinidine interaction via mixed-effect modelling. Clin Pharmacokinet 1992; 22: 66–74PubMedCrossRefGoogle Scholar
  68. 68.
    Jerling M, Merlé Y, Mentré F, et al. Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6 — an evaluation with the nonparametric maximum likelihood method. Br J Clin Pharmacol 1994; 38: 453–62PubMedCrossRefGoogle Scholar
  69. 69.
    Bauer LA, Horn JR, Pettit H. Mixed-effect modeling for detection and evaluation of drug interactions: digoxin-quinidine and digoxin-verapamil combinations. Ther Drug Monit 1996; 18: 46–52PubMedCrossRefGoogle Scholar
  70. 70.
    Ludden TM. Evaluation of potential drug-drug interactions using the population approach. In: Aarons L, Balant LP, Danhof M, et al., editors. The population approach: measuring variability in response, concentration and dose. Luxembourg: Office for Official Publications of the European Communities, 1997: 40–5Google Scholar
  71. 71.
    Grasela TH, Fiedler-Kelly J, Cox E, et al. Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. J Clin Pharmacol 1999; 39: 373–84PubMedCrossRefGoogle Scholar
  72. 72.
    Thomson AH, Kerr S, Wright S. Population pharmacokinetics of caffeine in neonates and young infants. Ther Drug Monit 1996; 18: 245–53PubMedCrossRefGoogle Scholar
  73. 73.
    Antal EJ, Grasela TH, Smith RB. An evaluation of population pharmacokinetics in therapeutic trials. Part III. Prospective data collection versus retrospective data assembly. Clin Pharmacol Ther 1989; 46: 552–9PubMedCrossRefGoogle Scholar
  74. 74.
    Yukawa E, Nomiyama N, Higuchi S, et al. Lithium population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens. Ther Drug Monit 1993; 15: 75–82PubMedCrossRefGoogle Scholar
  75. 75.
    Yukawa E, Aoyama T. Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data. J Clin Pharmacol 1996; 36: 752–9PubMedGoogle Scholar
  76. 76.
    Yukawa E, Honda T, Ohdo S, et al. Population-based investigation of relative clearance of digoxin in Japanese patients by multiple trough screen analysis: an update. J Clin Pharmacol 1997; 37: 92–100PubMedGoogle Scholar
  77. 77.
    Yukawa E, To H, Ohdo S, et al. Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics. J Clin Pharmacol 1997; 37: 1160–7PubMedGoogle Scholar
  78. 78.
    Yukawa E, To H, Ohdo S, et al. Detection of a drug-drug interaction on population-based phenobarbitone clearance using nonlinear mixed-effects modeling. Eur J Clin Pharmacol 1998; 54: 69–74PubMedCrossRefGoogle Scholar
  79. 79.
    Yukawa E, Hokazono T, Funakoshi A, et al. Epidemiologic investigation of the relative clearance of haloperidol by mixed-effect modeling using routine clinical pharmacokinetic data in Japanese patients. J Clin Psychopharmacol 2000; 20: 685–90PubMedCrossRefGoogle Scholar
  80. 80.
    Jann MW, Ereshefsky L, Saklad SR, et al. Effects of carbamazepine on plasma haloperidol levels. J Clin Psychopharmacol 1985; 5: 106–9PubMedCrossRefGoogle Scholar
  81. 81.
    Vozeh S, Steimer J-L. Feedback control methods for drug dosage optimisation. Concepts, classification and clinical application. Clin Pharmacokinet 1985; 10: 457–76PubMedCrossRefGoogle Scholar
  82. 82.
    Jelliffe RW, Schumitzky A, Bayard D, et al. Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new ‘multiple model’ dosage design, bayesian feedback and individualised target goals. Clin Pharmacokinet 1998; 34: 57–77PubMedCrossRefGoogle Scholar
  83. 83.
    Walson PD. Therapeutic drug monitoring in special populations. Clin Chem 1998; 44: 415–9PubMedGoogle Scholar
  84. 84.
    Jerling M. Dosing of antidepressants — the unknown art. J Clin Psychopharmacol 1995; 15: 435–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2001

Authors and Affiliations

  • Marianne Gex-Fabry
    • 1
  • Luc P. Balant
    • 1
  • Androniki E. Balant-Gorgia
    • 2
  1. 1.Clinical Research Unit, Department of PsychiatryGeneva University HospitalsSwitzerland
  2. 2.Therapeutic Drug Monitoring Unit Department of PsychiatryGeneva University HospitalsSwitzerland

Personalised recommendations